Abstract Research Article
IntroductIon
Noninvasive ventilation (NIV) is one of the interventions that have been used to facilitate weaning and prevent reintubation. Previous studies demonstrated the benefit of NIV in reduction of mortality, ventilator-associated pneumonia (VAP), and intensive care unit (ICU) and hospital length of stay. [1] [2] [3] NIV was proven to be beneficial in chronic obstructive pulmonary disease (COPD) exacerbation, [4] cardiogenic pulmonary edema, [5] and postsurgery patients. [6] For postextubation, the benefit of NIV in reduction of reintubation rate was primarily demonstrated in high-risk groups including advance age and cardiac or pulmonary diseases. [3, 7, 8] However, the benefit of utilization of NIV during postextubation in mixed medical ICU population has been conflicting. [7, [9] [10] [11] NIV has physiological benefit from positive end-expiratory pressure (PEEP) and pressure support (PS). PEEP is known to increase alveolar size and recruitment, improve gas exchange, improve lung compliance, reduce intrapulmonary shunt, and reduce work of breathing. [12, 13] PS can improve alveolar ventilation and allows some respiratory muscle rest during the inspiratory phase.
Targeted-volume NIV, bilevel positive airway pressure, allows for the setting of fixed tidal volume (TV) in which the system output automatically adjusts pressure to achieve the predetermined TV. Targeted-volume NIV has only been previously studied in obesity hypoventilation syndrome, [14, 15] COPD, [16] hypercapnic respiratory failure, [17] and chest wall deformity population. [18] We hypothesized that the application of targeted-volume NIV immediately after planned extubation would decrease reintubation rate, extubation failure rate, and other outcomes compared to standard oxygen therapy. At present, targeted-volume ventilation mode has been installed in many commercially available NIV devices.
MaterIals and Methods

Study design
This study was a randomized, controlled trial, conducted during the period from May 2016 to February 2017, in 16-bed medical ICU. This study was approved by the Ethics Committee, and this study was also registered to Clinical Trial website.
Patients' selection
Patients, who passed weaning process by spontaneous breathing trial with low-pressure support ventilation or T-piece, and met the readiness criteria for extubation, [19] without excessive copious secretion, passed cough leak test, and vital sign stability without high-dose vasopressor, were enrolled in the study. [20] Inclusion criteria were as follows: (a) age 18 years or older; (b) on invasive mechanical ventilation for a period longer than 48 hrs due to acute respiratory failure; (c) already weaned from invasive mechanical ventilation and ready for extubation; (d) and no facial abnormality or trauma or recent facial surgery. Exclusion criteria were as follows: (a) tracheostomized patients; (b) previous intubation in this current admission; (c) intubation due to COPD exacerbation or cardiogenic pulmonary edema; (d) and refusal to participate in the study. Informed consents were obtained from patients or the designated next of kin of the patients.
Randomization
Eligible patients were randomly assigned into 1:1 ratio to the application of targeted-volume NIV or oxygen mask. Randomization into assigned groups was performed using a mixed block. Assigned group randomizations were placed in sealed opaque envelopes which were labeled with the order of randomization.
Targeted-volume noninvasive ventilation
After extubation, proper size full face silicone mask (Amara Respironics full face mask, size S, M, and L) was fitted for each patient and adjusted to confirm and ensure patients' comfort. Average volume-assured PS (AVAPS) (Philips Respironics) machines were utilized in this study. The device was set at the targeted, delivered TV of 6 ml/kg of ideal body weight. End-expiratory positive airway pressure (EPAP) was set at 4 cm of water or equal to the last PEEP level of the invasive mechanical ventilation setting. Minimum inspiratory positive airway pressure (IPAP minimum ) was set equal to EPAP + 4 cm of water, and maximum inspiratory positive airway pressure (IPAP maximum ) was set to 26 cm of water. The device was set at the backup rate of 12 breaths/min. EPAP was increased by 2 cm of water to maintain SpO2 above 90%. Humidification Level 2 was also utilized during the study. In addition, 6 lpm of oxygen supplementation was added to targeted-volume NIV through T-connector. The targeted-volume NIV with 6 lpm of oxygen supplementation was utilized continuously for 24-h postextubation. After 24 h of usage, NIV was replaced by a nasal oxygen cannula.
Oxygen mask
Patients assigned to oxygen mask group were administrated simple oxygen mask with humidification at fixed oxygen flow of 6 lpm immediately after extubation. After 24 hrs of usage, an oxygen mask was replaced by a nasal oxygen cannula.
Monitoring
All patients in the study received standard nursing care in medical ICU and were monitored for vital signs (heart rate, respiratory rate, and blood pressure) and oxygen saturation. Blood gas was drawn from an arterial line or radial artery at baseline, 30 mins, 2 hrs, and 24 hrs after extubation. Patients were followed up until discharge or at least 28 days after extubation.
Outcomes
The primary outcome of this study was reintubation rate within 48 hrs after extubation. Extubation failure rate within 48 hrs, reintubation rate within 28 days, mortality (both in ICU and in hospital), hospital or ventilator associated pneumonia (HAP/ VAP), and ICU and hospital length of stay were monitored as the secondary outcomes of the study. We also collected data of patients' comfort by using visual analog scale (VAS) and side effects of the device such as pressure sore, nasal congestion, facial pain, and serious complications including aspiration, hypotension, and pneumothorax.
We defined patients with extubation failure as follows: unstable blood pressure (systolic blood pressure >180 mmHg or <90 mmHg), extreme tachycardia (heart rate >140 bpm), life-threatening cardiac arrhythmia, respiratory distress (respiratory rate >30 breaths/min), decreased level of consciousness, uncontrolled agitation, hypoxemia (PaO2 <60 mmHg) or hypercapnia (PaCO2 >50 mmHg), and inability to clear secretion. [9] If patients met the extubation failure criteria, reintubation might be considered. However, the decision for reintubation or using other rescue interventions, such as NIV or high-flow nasal cannula (HFNC), to prevent reintubation was made by ICU physicians to reduced bias of investigators.
Statistical analysis
Since the study of Ornico et al. reported reintubation rate in NIV and oxygen mask group were 5% and 39%, respectively. [9] We used the study power of 80% and α-error of 5% and calculated sample size to be 52 patients (26 patients in each group). We expected dropout rate of 10%; hence, the final calculated sample size was 58 patients (29 patients in each intervention).
Quantitative variables were compared between two interventions using Student's t-test or Mann-Whitney U test. Chi-squared or Fisher's exact test was used to compare proportion between groups. For consecutive measurement for repeated data, we used the analysis of the linear mixed-effect model. The Kaplan-Meier curve was used to estimate the probability of intubation free after extubation. The study was analyzed by using intention-to-treat analysis. Stata version 12.1 software was utilized.
results
From May 2016 to February 2017, 588 patients were admitted to medical ICU. A total of 438 patients were excluded since they did not meet the inclusion criteria. Thirty-eight patients declined to participate in the study. Fifty-four patients met the exclusion criteria. Finally, 58 patients were enrolled in the study and randomized into two groups. One patient in the targeted-volume NIV group discontinued the device immediately after the trial due to pressure intolerance. This patient was analyzed in the targeted-volume NIV group according to the intention-to-treat analysis protocol [ Figure 1 ].
Targeted-volume NIV group and oxygen mask group were similar in baseline characteristics as shown in Table 1 . All patients were followed up until discharge from the hospital.
No reintubation within 48 hrs was observed in targeted-volume NIV group whereas five patients in the oxygen mask group (17.24%) were reintubated (P = 0.052) [ Figure 2 ]. Furthermore, no one in targeted-volume NIV group developed extubation failure compared to 12 patients in oxygen mask group (41.38%) (P < 0.001). In those 12 patients who developed extubation failure within 48 hrs, five patients were reintubated (17.24%), five patients received rescue conventional targeted-pressure NIV (17.24%), and two patients received rescue HFNC (6.89%) [ Figure 3 ]. Among 12 patients who developed extubation failure, causes of extubation failure included respiratory distress (33.33%), hypoxemia (33.33%), hypercapnia (16.67%), extreme tachycardia (8.33%), and inability to clear secretion (8.33%).
There was a trend toward lower ICU length of stay in targeted-volume NIV group compared to oxygen mask group (6[5] Despite lower PaO2 observed in the targeted-volume NIV group at 30 mins and 2 hrs, the difference was not statistically significant at 24 hrs (P = 0.510). PaO2 values were also normal throughout the monitoring period in targeted-volume NIV group. There was no statistically significant difference in PaCO2 between two groups. However, heart rate and respiratory rate were lower in targeted-volume NIV group as shown in Figure 4 .
The targeted-volume NIV setting, delivery values, leakage data, and hours of usage are shown in Table 3 . Patients' discomfort assessed by VAS was not different between groups except mask leakage was more frequently observed in the targeted-volume NIV group (46.43%) compared to 0% in oxygen mask group. No serious complications, including hypotension, aspiration, or pneumothorax, were observed during the study.
dIscussIon
Our study demonstrates the benefit of targeted-volume NIV in reducing extubation failure rate when it was applied prophylactically during postextubation in mixed medical ICU patients. We also observed a trend toward reduction in reintubation rate within 48 hrs.
There are different strategies for applying NIV in the postextubation period: for weaning (weaning strategy) in cases of weaning difficulties (one or more spontaneous breathing trial failures), to prevent postextubation failure (preventive strategy) or to treat postextubation failure (curative or rescue strategy). [21] According to currently available data, the use of NIV immediately postextubation as a preventive strategy in high-risk group may offer benefit. Thille et al., recently, showed the benefit of prophylactic NIV after extubation in reduction of reintubation in high-risk medical ICU patients. [8] However, their study also included postoperative patients (20%). The previous meta-analysis by Bajaj et al. also demonstrated that the use of NIV in high-risk group resulted in reduction in reintubation, [7] concurrent with recent recommendation from the American College of Chest Physicians and American Thoracic Society which endorsed the use of NIV during postextubation only in high-risk group. [22] Nevertheless, the benefit of the routine use of NIV to prevent reintubation has been conflicting. Paper by Ornico et al. demonstrated a significant reduction in reintubation with the use of NIV during postextubation. [9] However, their study included some proportion of COPD (35%), cardiogenic pulmonary edema (10%), and postsurgery patients (25%) which may have favored the outcome of the NIV group.
Our study is the first study that utilized targeted-volume NIV during postextubation as the preventive strategy in mixed medical ICU patients. Reduction in extubation failure was observed with the use of targeted-volume NIV in our study despite excluding COPD exacerbation and cardiogenic pulmonary edema population.
Even though reintubation rate after extubation in the targeted-volume NIV group appeared to be lower than oxygen mask group, the difference did not achieve statistically significance (P = 0.052). Our study allowed the attending ICU physician to utilize other rescue interventions besides reintubation when extubation failure developed, as the real-world practice fashion. This strategy could have caused falsely low reintubation rate in our study since this strategy apparently prevented reintubation in extubation failure patients in our study. However, this practice has to be conducted with caution. Prior studies had demonstrated that the use of NIV in the group of extubation failure as curative or rescue strategy may be associated with higher mortality. [23, 24] Subgroup analysis of the high-risk groups defined as age >65 years old and/or the presence of cardiac or pulmonary diseases revealed similar results (data not shown).
Conventional targeted-pressure NIV was not tested against targeted-volume NIV in our study. However, we hypothesized that the targeted-volume NIV might be more suitable than conventional targeted-pressure NIV due to more steady TV. In this study, respiratory rate and heart rate during postextubation were significantly lower in targeted-volume NIV group compared to oxygen mask group which may indicate reduction in work of breathing from respiratory muscle resting [9, 25] [ Figure 4 ]. On the other hand, excessive TV may result in an excessive leakage, causing suboptimal benefit of NIV and may lead to NIV failure. Recent study on NIV outcome demonstrated that high expiratory TV (Vte) was associated with NIV failure particularly when Vte was above 9.5 ml/kg of predicted body weight. [26] In this study, the mean Vte was optimal (8.63 ± 1.41 ml/kg). Excessive TV and high transpulmonary pressure could potentially promote ventilator-induced lung injuries associated with detrimental outcomes. [27] However, the difference between the setup and the delivered TV (6.11 ± 0.27 vs 8.63 ± 1.41 ml/kg) was observed in our study most likely explained by the patients' own inspiratory effort. This is an important message that targeted-volume NIV mode is not totally risk free, and surveillance is still required. We also demonstrated that the targeted-volume NIV was well tolerated with minor observed side effects.
Previous studies in targeted-volume NIV demonstrated its benefit in obesity hypoventilation syndrome, [14, 15] COPD, [16] hypercapnic respiratory failure, [17] and chest-wall deformity population. [18] Our study demonstrated the safety and feasibility of the use of targeted-volume NIV in postextubation as the preventive strategy and our preliminary data demonstrated its efficacy to decrease extubation failure. In general, reintubation rate is modest at around 10%-20%. [28] However, extubation failure has been shown to be associated with many detrimental outcomes including increased mortality, increased ICU, and hospital length of stay as well as increased incidence of VAP. [29] We believe that the use of targeted-volume NIV could be of benefit in this postextubation period as the preventive strategy. However, further study on cost-effectiveness of utilization of this intervention is crucial.
Limitation
Our study was a single-center study with relatively small sample size; hence, multicenter study with larger sample size is warrant. We only studied the reintubation and extubation failure rates within 48 hrs as we utilized the previously defined terms. [30] [31] [32] The outcomes of reintubation and extubation failure rates after 48 hrs might be of benefit as some studies demonstrated that the reintubation rate can occur up to 7 days. [33] Conventional targeted-pressure NIV and HFNC were not utilized for comparison in our study, as we aimed to compare targeted-volume NIV with standard oxygen therapy. In perspective, targeted-volume NIV could be formally tested against targeted-pressure NIV and/or HFNC in the future study.
conclusIons
Targeted-volume NIV in immediate postextubation in mixed medical ICU patients as the preventive strategy showed benefit in reduction of extubation failure within 48 hrs after extubation and a trend toward reduction in reintubation rate in 48 hrs, ICU length of stay, and hospital length of stay after extubation.
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